Highlights of the 45th Annual Meeting of the American Society of Hematology

Lawrence M. Prescott, Thomas E. Witzig, John P. Leonard, Jeffrey E. Lancet, Norbert Vey, Tahir Latif, John M. Brooks, Christos Emmanoulides, Sean D. Sullivan, Benjamin Brenner, Raffaele Landofi

Research output: Contribution to journalArticlepeer-review


More than 20,000 physicians, research scientists, nurses, and other health care professionals from around the world gathered in San Diego, California, from December 6 to 9, 2003, to attend the 45th Annual Meeting of the American Society of Hematology and to hear about the latest developments in the prevention, diagnosis, control, treatment, and palliative care of malignant and nonmalignant hematologic diseases. Several novel therapeutic modalities of special interest included a radioimmunotherapeutic approach for relapsed or refractory non-Hodgkin's lymphoma; an antisense and chemotherapeutic combination for mantle-cell lymphoma; a new farnesyl transferase inhibitor for difficult-to-treat conditions, including acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia; and a unique arsenic compound for myelodysplasia. Other studies of interest discussed a unique drug to combat oral mucositis, new methods to enhance the prevention of thrombosis in orthopedic surgery and in recurrent pregnancy loss, the value of low-dose aspirin in polycythemia vera, an analysis elucidating the reasons for renal impairment during therapy for multiple myeloma, and a determination of the high expense of hospitalizations for neutropenia and the possible reasons for this during chemotherapy for patients with non-Hodgkin's lymphoma.

Original languageEnglish (US)
Pages (from-to)98-102
Number of pages5
JournalP and T
Issue number2
StatePublished - Feb 2004

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Highlights of the 45th Annual Meeting of the American Society of Hematology'. Together they form a unique fingerprint.

Cite this